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A Case-Control Study of Apolipoprotein E 
Genotypes in Alzheimer’s Disease 
Associated with Down’s Syndrome 
W. A. van Gool, MD,” H. M. Evenhuis, MD,t  and C. M. van Duijn PhD,$ on Behalf of the Dutch Study 
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The prevalence of clinical signs and neuropathological findings of Alzheimer’s disease (AD) is high in Down’s syndrome 
(DS). In the general population, the apolipoprotein E (ApoE) €4 isoform is an important risk marker for AD. We 
studied the allelic frequencies of ApoE in 26 DS cases fulfilling clinical diagnostic criteria for AD and in 26 DS 
controls matched for age, sex, and premorbid level of mental retardation. A meta-analysis of data available in the 
literature was used for comparison with allele frequencies in other AD and control populations. ApoE type 2, 3, or 4 
allele frequencies were not significantly different in AD-DS cases and DS controls. The ApoE €4 frequency in DS 
cases with AD (0.14; CI, 0.06-0.26) was significantly lower than in any other AD population studied so far and it is 
within the range of nondemented controls from the general population. These findings suggest that ApoE €4 does 
not significantly affect the pathogenesis of AD in DS patients. 
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Prevalence estimates of dementia in populations with 
Down’s syndrome (DS) amount to 8, 5 5 ,  and 759% in 
the fifth, sixth, and seventh decades, respectively [ 1). 
In virtually all cases of DS over 40 years of age senile 
plaques and neurofibrillary tangles characteristic of 
Alzheimer’s disease (AD) are present within one or 
more regions of the brain [2]. Increased expression of 
the P-amyloid precursor gene located on chromosome 
21 is thought to underly the development of these 
abnormalities in trisomy 21 12). 
In the general population, the apolipoprotein E 
(ApoE) €4 isoform is an important risk marker for de- 
veloping AD, and in familial forms of A D  €4 ApoE 
confers an earlier onset of dementia [3]. These obser- 
vations fostered the hypothesis that ApoE rather than 
P-amyloid plays a central role in the pathogenesis of 
A D  131. Previous observations on the frequency of €4 
ApoE in DS yielded figures ranging from 0.03 to 0.22, 
suggesting that trisomy 21 itself does not segregate 
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with a specific ApoE genotype {4-71. However, nei- 
ther of these reports specified whether the DS subjects 
studied showed clinical signs of AD. If an ApoE €4- 
driven process of paired helical filament formation has 
a primary role in causing clinical and neuropathological 
signs of A D  (81, ApoE genotype can be expected to 
modulate the risk or age of onset of dementia in DS 
as well. To investigate this hypothesis, we compared 
the allelic frequencies of ApoE between DS cases ful- 
filling clinical diagnostic criteria for A D  and nonde- 
mented DS controls. A meta-analysis of data available 
in the literature was used for comparison with allele 
frequencies in control and A D  populations from the 
general population. 
Materials and Methods 
Subjects were ascertained through eight institutions for per- 
sons with mental retardation (specified in the footnotes). 
Patients were included as AD-DS cases according to the 
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following criteria: ( 1  ) a diagnosis of DS based o n  karyotyp- 
ing; (2) a clinical diagnosis of dementia based on evidence 
for memory disturbances combined with aphasia, apraxia, 
changes in the original level of spatial or temporal orienta- 
tion, or personality changes, all based on longitudinal obser- 
vations in daily circumstances, interfering with work or usual 
social activities or personal relationships, not occurring exclu- 
sively during the course of delirium; (3) a score of 20 or more 
or increase of 7 points or more on the cognitive subscale of 
the Dementia Questionnaire for Mentally Retarded Persons 
[91; ( 4 )  an estimated time since onset of symptoms of at least 
1 year; ( 5 )  absence of abnormalities on medical, psychiatric, 
neurological, and laboratory examination explaining the men- 
tal deterioration; especially severe hearing loss and hypothy- 
roidism were excluded. Subjects were classified as DS control 
on the basis of (1) a karyotype-verified diagnosis of DS; (2) 
absence of dementia, indicated by absence of changes in func- 
tioning in daily circumstances in the period preceding inclu- 
sion. Subjects were classified as AD cases or controls by 
physicians who knew the patients for years before the begin- 
ning of this study. Cases and controls were matched for sex, 
age, and for premorbid level of functioning on  the basis of 
scores on a Dutch standard instrument measuring adaptive 
functioning. used in all participating institutions [lo]. Ap- 
proval for the study was obtained from the ethics review 
committees of all participating institutions (see footnotes). In  
all participants consent was obtained from relatives and if 
possible from the subjects themselves. Resistance of partici- 
pants to venapuncture, either in words or actions, was inter- 
preted as withdrawal of consent leading to exclusion from 
the study. 
Genomic DNA samples were prepared from peripheral 
white blood cells. ApoE genotyping was performed in the 
coordinating center on coded samples without knowledge of 
the clinical diagnosis. About 1 to 2 pg of D N A  was isolated 
from 20 ml EDTA-blood. ApoE genotype was determined 
using a modification of the method of Hixson and collabora- 
tors [ 111; to visualize ApoE genotypes on agarose gel the 
3’-primer was elongated with a 20-nucleotide AT tail (Rey- 
mer PWA, Groenemeyer BE, van de Burg R, Kastelein JJP, 
unpublished data). Polymerase chain reactions (PCRs) were 
carried out in standard buffer (50 mhf KCI, 10 mM Tris-OH, 
p H  9.0, O.OlfZ gelatin, 1.5 mM MgCI,, 0 .19 Triton X-100) 
with 0.5 (*M concentration of primer, 100 pM dNTP, and 
0.2 mg/ml bovine serum albumin. After amplification (with- 
out  dimethyl sulfoxide; 30 seconds at 94°C 1 minute at 60°C, 
1 minute at 7OoC, 30 cycles with 0.5 units Supertaq 
[Sphaero-Q, UK]) and digestion with 4 units CfoI ({Promega, 
USA] 1.5 hour at 37°C) PCR/digesrion fragments could be 
separated on a 5?f1 agarose gel (Agarose MP, Boehringer 
Mannheim, Germany) and visualized by ethidium bromide 
staining (Reymer PWA, Groenemeyer BE, van de Burg R, 
Kastelein JJP, unpublished data). Prior power calculations 
showed that a minimum of 50 alleles should be studied in 
each group to detect at least a twofold excess of ApoE €4 in 
AD-DS compared with DS controls, with an a- and p-error 
of 0.05 and 0.10, respectively. 
For the meta-analysis of ApoE allele frequencies in con- 
trols and AD patients from the general population, a com- 
puter search in Medline for the period August 1093 to Octo- 
ber 1994 was performed using “apolipoprotein E ’  and 
“Alzheimer’s disease” as search terms. Retrieved articles or 
letters to the editor, excluding abstracts, in which original 
research was described were identified. We only included 
studies if (1) well-described diagnostic criteria for A D  were 
used, (2) data presentation was in such a manner that €4 
ApoE allele frequencies could be calculated, and (3) the A D  
group contained at least 25 patients. 
Allele frequencies were estimated by counting alleles and 
calculating sample proportions. Comparisons of genotype 
frequencies and allele frequencies were made using the x2 
statistic or  Fisher’s exact test. as appropriate. Differences in 
age of onset and duration of symptoms according to the pres- 
ence of the €4 allele in AD-DS cases were analyzed statisti- 
cally by the unpaired r test. 
Results 
A total of 5 2  subjects with DS were included in the 
study. There were no significant differences between 
the AD-DS cases and DS controls in age, sex, and 
premorbid level of functioning (Table 1). The fre- 
quency of the most common genotype (ApoE 3 / 3 )  was 
similar in both groups. The ApoE type 2, 3 ,  and 4 allele 
frequencies were not significantly different in AD-DS 
cases and DS-control subjects (see Table 1). Age of 
onset in AD-DS with (mean {?SD}, 54.1 1k7.91 
years) and without €4-alleles (54.6 Ck6.51 years) was 
not significantly different ( p  = 0.86). Also the duration 
of symptoms in €4-carriers (3.6 [ t 1.7) years) was simi- 
lar to those without the €4-allele (4.9 Et2 .73  years) 
( p  = 0.25). 
The results of the meta-analysis of studies performed 
in non-DS populations showed increased ApoE €4 al- 
lele frequencies in all cohorts with AD, which were most 
prominent in those with familial onset and with late- 
onset of A D  (Table 2 and Fig). The ApoE €4 frequency 
found in the AD-DS cases is significantly lower than 
in any other A D  population studied so far, and it is 
within the range of published general population data 
on nondemented subjects (see Table 2 and Fig) [12]. 
Discussion 
Since the pivotal observations of the Duke University 
group on the association between the ApoE €4 allele 
and A D  [6, 19, 20, 22,  231, numerous studies have 
replicated this finding in various populations of AD 
patients with different hereditary components, ages of 
onset, and ethnic backgrounds (see Fig for references). 
The €4 ApoE allele frequency in the AD-DS cases 
described here is particularly interesting because it is 
the first clinically diagnosed A D  population of reason- 
able size in which such low figures were found. In our 
population of AD-DS cases of ApoE €4 frequency was 
only slightly higher than in nondernented DS controls 
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Table 1. Patient Characteristics, ApoE Genotypes. and A flefe Frequencies 
DS Controls AD-DS 
Number of subjects 26 26 
MenIWomen 10116 10116 
Age (yr) (SD, range) 55.0 (8.6, 41-70) 54.5 (7.4, 42-71) 
n Frequency (959Z C1) n Frequency (95% CI) 
Level of retardation 
Profound 1 0.04 (0.00-0.20) 1 0.04 (0.00-0.20) 
Severe 16 0.62 (0.4 1-0.80) 17 0.65 (0.44-0.83) 
Moderate 9 0.35 (0.17-0.56) 8 0.31 (0.14-0.52) 
Genotype 
414 
313 
212 
413 
412 
213 
€ 2  
€3 
€4 
Allele frequencies 
- 
17 
1 
4 
1 
3 
6 
41 
5 
- 
0.65 (0.44-0.83) 
0.04 (0.00-0.20) 
0.15 (0.04-0.35) 
0.04 (0.00-0.20) 
0.12 (0.03-0.30) 
0.12 (0.04-0.23) 
0.79 (0.65-0.89) 
0.10 (0.03-0.21) 
- 
16 
7 
3 
3 
42  
7 
- 
- 
- 
0.62 (0.4 1-0.80) 
- 
0.27 (0.12-0.48) 
- 
0.12 (0.03-0.30) 
0.06 (0.01-0.16) 
0.81 (0.68-0.90) 
0.14 (0.06-0.26) 
ApoE = apolipoprotein E; DS = Down's syndrome; A D  = Alzheimer's disease; CI = confidence interval. 
Table 2. ApoE €4 Allele Frequencies in Different A D  
and Control Populations 
Study Population ApoE €4 Allele 
Type n Frequency 95% CI 
Early onset familial AD" 286 0.42d 0.36-0.48 
Early onset sporadic ADa 336 0.28' 0.23-0.33 
Late onset familial AD" 1,202 0.48' 0.45-0.51 
Late onset sporadic AD" 3,124 0.37R 0.35-0.39 
Nondemented controlsb 2,000 0.14 0.12-0.16 
DS controlsC 52 0.10 0.03-0.2 1 
AD-DS casesC 52 0.14 0.06-0.26 
"Results from meta-analysis (see Materials and Methods and Fig). 
bTaken from Menzel and co-workers 112) (see also Fig). This group 
served as reference for comparison of apolipoprotein E (ApoE) €4 
allele frequencies in the other groups using the x 2  statistic. 
'This study (see also Fig and Table 1). 
' x x L  = 136.7, df = 1, p < 0.0001. 
'x '  = 40.6, df = 1, p < 0.0001. 
'xi = 118.5, df = 1, p < 0.0001. 
'x' = 320.3, df = 1, p < 0.0001. 
A D  = Alzheimer's disease; CI = confidence interval; DS = Down's 
syndrome. 
and it was similar to that in nondemented controls from 
the general population C 12). Several explanations may 
account for this unexpected observation. 
First, difficulties in diagnosing A D  in the general 
population are well established and diagnosing this 
condition in individuals with mental retardation is even 
more difficult than in persons with normal intelligence 
and psychosocial functioning C4 1). Applying diagnostic 
criteria designed for populations without mental retar- 
dation may elicit numerous false-positive classifications 
if used in a DS population. This may lead to underesti- 
mation of real differences in €4 allele frequencies be- 
tween AD-DS and DS controls. However, to mini- 
mize the risk of bias we studied institutionalized 
patients, which enabled us to use criteria relying 
heavily on long-standing, careful observations in daily 
life, using comparison with former actual levels of psy- 
chosocial functioning, rather than applying a single clin- 
ical and neuropsychological assessment. Also careful 
exclusion of various conditions other than A D  that can 
impair the level of functioning in persons with DS 
should have minimized diagnostic misclassifications. 
Second, excess mortality in AD-DS cases carrying €4 
alleles may have obscured hypothetical true differences 
between cases and controls. However, we found no 
effects of the €4 allele presence on disease duration, 
rendering this explanation unlikely. Moreover, the €4 
allele frequencies in AD-DS cases and in DS controls 
reported here are within the range of those found in 
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other populations with trisomy 2 1 {4-71. The possible 
relation between ApoE phenotypes and dementia in 
DS remained unclear in these previous studies, be- 
cause the mental status of the subjects was not eval- 
uated. 
That we were unable to detect significant differences 
in €4 allele frequency between demented and nonde- 
mented persons with DS, between patients with early 
and late onset of dementia, and between AD-DS cases 
with short and long duration of dementia symptoms is 
consistent with the view that the clinical and neuro- 
pathological signs of A D  in trisomy 21 should mainly 
be attributed to increased formation of P-amyloid. Ap- 
parently ApoE €4 does not further increase the high 
risk of developing AD in DS. Despite the fact that 
ApoE is present in senile plaques in AD-DS [42) ,  the 
€4 isotype of this protein appears neither to influence 
the clinical expression (this study) nor the neuropatho- 
logical features of this disease in DS [4 ,  5 ,  71, sug- 
gesting that the relative contribution of either ApoE- 
or P-amyloid-driven processes in the pathogenesis of 
AD differs between populations with trisomy 21 and 
those with a normal karyogram. This difference pro- 
vides additional support for the idea that AD is an 
etiologically heterogeneous disorder, which is also ex- 
emplified by the presence of sporadic forms of AD, 
autosomal dominant forms with mutations in the chro- 
mosome 21 amyloid precursor protein (APP) gene, 
and familial forms of AD with linkage to chromosomes 
14 and 19, and to another unidentified locus 1431. 
A population with such a high risk for developing 
AD, as the DS population studied here, is extremely 
suitable to study putative protective factors for not de- 
veloping AD. Several studies suggest that €2 ApoE 
may reduce the risk of developing AD 123, 24, 26, 
401. This observation led to the hypothesis that ApoE 
genotypes may modulate the risk for AD by differen- 
tially affecting the rate of phosphorylation of 7 to form 
neurofibrillary tangles [3].  According to this hypothe- 
sis €4 ApoE would stimulate tangle formation, whereas 
€2 would protect against neurofibrillary degeneration. 
However, we found no excess €2 alleles in our DS 
controls, not even among the 14 elderly nondemented 
DS individuals over 5 5  years of age (0.15 €2 alleles; 
confidence interval [CI], 0.04-0.35). Our study was 
initially designed to study differences in €4 allele fre- 
quencies, and given the low prevalence of €2 alleles, 
the power of our study may have been too limited 
to draw any conclusion concerning the absence of a 
protective allele €2 effect in this specific population. 
Apart from these considerations relating to the 
pathogenesis of AD, the present results may also have 
practical implications. When the first reports on the 
excess of €4 alleles in A D  appeared, several authors 
suggested that ApoE genotyping could be a tool for 
identifying individuals with increased risk for devel- 
oping AD C28, 30, 35, 44 ,  451 although preliminary 
analyses already predicted that the practical usefulness 
of ApoE genotyping for such a purpose will be poor in 
the general population 146, 471. Based on our present 
results it can be concluded that ApoE genotyping for 
diagnostic purposes will certainly not be feasible in DS 
populations. In a similar manner, it has been speculated 
that manipulation of the ApoE-driven pathogenetic 
pathways may offer new therapeutic opportunities I 1  7, 
40, 44, 481, whereas the present results strongly sug- 
gest that it is not useful to pursue such efforts in 
AD-DS patients. 
In conclusion, whatever the relative contribution of 
either ApoE or P-amyloid in the pathogenesis of AD 
may be in the general population, the absence of excess 
of €4 alleles in AD-DS patients as documented in our 
study suggests that the role ApoE €4 plays in causing 
AD in individuals with DS is of minor importance. 
This conclusion may have implications for future stud- 
ies into diagnostic and therapeutic efforts in AD-DS 
and it reinforces the idea that AD is an etiologically 
heterogeneous disorder. 
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